[go: up one dir, main page]

BRPI0905717A2 - Composição farmacêutica, processo para preparar uma composição farmacêutica e forma de dosagem farmacêutica - Google Patents

Composição farmacêutica, processo para preparar uma composição farmacêutica e forma de dosagem farmacêutica

Info

Publication number
BRPI0905717A2
BRPI0905717A2 BRPI0905717-0A BRPI0905717A BRPI0905717A2 BR PI0905717 A2 BRPI0905717 A2 BR PI0905717A2 BR PI0905717 A BRPI0905717 A BR PI0905717A BR PI0905717 A2 BRPI0905717 A2 BR PI0905717A2
Authority
BR
Brazil
Prior art keywords
pharmaceutical composition
pharmaceutical
preparing
dosage form
composition
Prior art date
Application number
BRPI0905717-0A
Other languages
English (en)
Inventor
Amar Lulla
Geena Malhotra
Original Assignee
Cipla Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cipla Ltd filed Critical Cipla Ltd
Publication of BRPI0905717A2 publication Critical patent/BRPI0905717A2/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BRPI0905717-0A 2008-01-11 2009-01-12 Composição farmacêutica, processo para preparar uma composição farmacêutica e forma de dosagem farmacêutica BRPI0905717A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
IN89MU2008 2008-01-11
IN489MU2008 2008-03-10
IN619MU2008 2008-03-24
PCT/GB2009/000083 WO2009087410A2 (en) 2008-01-11 2009-01-12 Solid pharmaceutical dosage form

Publications (1)

Publication Number Publication Date
BRPI0905717A2 true BRPI0905717A2 (pt) 2015-07-14

Family

ID=40510460

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0905717-0A BRPI0905717A2 (pt) 2008-01-11 2009-01-12 Composição farmacêutica, processo para preparar uma composição farmacêutica e forma de dosagem farmacêutica

Country Status (15)

Country Link
US (1) US20110028456A1 (pt)
EP (1) EP2249808A2 (pt)
JP (1) JP2011509283A (pt)
KR (1) KR20100134557A (pt)
CN (1) CN101951891A (pt)
AP (1) AP2010005341A0 (pt)
AU (1) AU2009203627A1 (pt)
BR (1) BRPI0905717A2 (pt)
CA (1) CA2712010A1 (pt)
CO (1) CO6290635A2 (pt)
MX (1) MX2010007645A (pt)
PA (1) PA8812601A1 (pt)
PE (1) PE20091550A1 (pt)
WO (1) WO2009087410A2 (pt)
ZA (1) ZA201005015B (pt)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2359812C (en) 2000-11-20 2004-02-10 The Procter & Gamble Company Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures
US7201920B2 (en) 2003-11-26 2007-04-10 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of opioid containing dosage forms
EA024980B1 (ru) 2009-02-17 2016-11-30 КРКА, д.д., НОВО МЕСТО Лекарственные формы, содержащие основание прасугреля или его фармацевтически приемлемые соли присоединения кислоты, и способы их приготовления
EP2279728A1 (en) * 2009-07-31 2011-02-02 Ranbaxy Laboratories Limited Solid dosage forms of HIV protease inhibitors
ES2569925T3 (es) 2009-09-30 2016-05-13 Acura Pharmaceuticals, Inc. Métodos y composiciones de disuasión del abuso
EP2515871B1 (en) * 2009-12-23 2015-09-23 ratiopharm GmbH Solid pharmaceutical dosage form of ticagrelor
CN103391770A (zh) * 2011-01-10 2013-11-13 细胞基因公司 环丙烷羧酸{2-[(1s)-1-(3-乙氧基-4-甲氧基-苯基)-2-甲烷磺酰基-乙基]-3-氧代-2,3-二氢-1h-异吲哚-4-基}-酰胺的口服剂型
TR201102067A1 (tr) 2011-03-03 2012-09-21 Sanovel İlaç Sanayi̇ Ve Ti̇caret Anoni̇m Şi̇rketi̇ Valsartan ve amlodipin kombinasyonları.
CN102188401B (zh) * 2011-05-10 2013-07-03 山东威高药业有限公司 一种非洛地平缓释片及其制备方法
CN102327272B (zh) * 2011-07-14 2013-08-14 海南锦瑞制药股份有限公司 一种口服固体药用组合物及其制备方法
MX356210B (es) * 2011-10-18 2018-05-18 Purdue Pharma Lp Formulaciones de polimero acrilico.
WO2013130785A2 (en) * 2012-03-01 2013-09-06 Bristol-Myers Squibb Company Extended release pharmaceutical formulations of water-soluble active pharmaceutical ingredients and methods for making the same
BR112014025041B8 (pt) 2012-05-31 2023-04-18 Merck Sharp & Dohme Composição farmacêutica
WO2013191668A1 (en) 2012-06-22 2013-12-27 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Compositions preventing hypertension comprising soluplus
CN103040833A (zh) * 2012-10-10 2013-04-17 盛世泰科生物医药技术(苏州)有限公司 一种伏立康唑的药物组合以及制备方法
WO2014085599A1 (en) 2012-11-30 2014-06-05 Acura Pharmaceuticals, Inc. Self-regulated release of active pharmaceutical ingredient
RU2505286C1 (ru) * 2012-12-29 2014-01-27 Открытое Акционерное Общество "Фармасинтез" Фармацевтическая композиция для лечения вич-инфекции, способ ее получения и способ лечения
WO2015070396A1 (zh) * 2013-11-13 2015-05-21 财团法人国防教育研究基金会 无肝副作用的对乙酰胺基酚新复方组合
CA2943728C (en) 2014-03-26 2020-03-24 Sun Pharma Advanced Research Company Ltd. Abuse deterrent immediate release biphasic matrix solid dosage form
CN104971045A (zh) * 2014-04-11 2015-10-14 上海宣泰医药科技有限公司 泊沙康唑药物组合物及其制备方法和药物制剂
GR1008554B (el) * 2014-06-12 2015-09-03 ΦΑΡΜΑΤΕΝ ΑΝΩΝΥΜΟΣ ΒΙΟΜΗΧΑΝΙΚΗ ΚΑΙ ΕΜΠΟΡΙΚΗ ΕΤΑΙΡΕΙΑ ΦΑΡΜΑΚΕΥΤΙΚΩΝ ΙΑΤΡΙΚΩΝ ΚΑΙ ΚΑΛΛΥΝΤΙΚΩΝ ΠΡΟΪΟΝΤΩΝ με δ.τ. ΦΑΡΜΑΤΕΝ, Φαρμακευτικο σκευασμα περιεχον εναν αντιμυκητιασικο παραγοντα τριaζολης και μεθοδος για την παρασκευη αυτου
KR101722564B1 (ko) * 2014-09-16 2017-04-03 강원대학교산학협력단 수-난용성 약물을 포함하는 고체분산체
CN104546788B (zh) * 2015-01-13 2018-01-23 上海信谊万象药业股份有限公司 一种辛伐他汀片的制备方法
JP5871294B1 (ja) * 2015-02-27 2016-03-01 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 即時放出経口錠剤
JP2017014119A (ja) * 2015-06-26 2017-01-19 東和薬品株式会社 経口医薬組成物
WO2017040607A1 (en) 2015-08-31 2017-03-09 Acura Pharmaceuticals, Inc. Methods and compositions for self-regulated release of active pharmaceutical ingredient
US9687475B1 (en) 2016-03-24 2017-06-27 Ezra Pharma Llc Extended release pharmaceutical formulations with controlled impurity levels
WO2018127088A1 (en) * 2017-01-06 2018-07-12 Sunshine Lake Pharma Co., Ltd. Lurasidone solid dispersion and preparation method thereof
IL269668B2 (en) 2017-03-30 2023-09-01 Merck Patent Gmbh Pharmaceutical preparations containing (s)-[2-chloro-4-fluoro-5-(7-morpholin-4-ylquinazolin-4-yl)phenyl]-(6-methoxy-pyridazin-3-yl)methanol and their preparation
CN107184559B (zh) * 2017-06-02 2018-07-31 广东赛康制药厂有限公司 一种盐酸二甲双胍缓释片及其制备方法
JP6858729B2 (ja) * 2018-05-25 2021-04-14 ▲財▼▲団▼法人国防教育研究基金会National Defense Education And Research Foundation 肝臓に対する副作用がない、新しいアセトアミノフェン複合組成
CN110585156B (zh) * 2019-10-24 2021-09-28 中国人民解放军军事科学院军事医学研究院 一种对乙酰氨基酚缓释制剂及其3d打印制备方法
CN110917156A (zh) * 2019-12-18 2020-03-27 乐普制药科技有限公司 一种依折麦布口含片及其制备方法
CN111529497A (zh) * 2020-02-11 2020-08-14 兆科(广州)肿瘤药物有限公司 一种吉马替康药物固体分散组合物及其制备方法
US20240226303A9 (en) * 2021-03-04 2024-07-11 Reckitt Benckiser Health Limited Novel composition
JP2024115533A (ja) * 2023-02-14 2024-08-26 沢井製薬株式会社 コーティング顆粒、コーティング顆粒を含む製剤及びそれらの製造方法
KR20250014832A (ko) * 2023-07-21 2025-02-03 현대약품 주식회사 약학 조성물 및 이의 제조 방법

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69222182T2 (de) * 1991-12-18 1998-02-26 Warner Lambert Co Verfahren für die herstellung einer festen dispersion
DE19509807A1 (de) * 1995-03-21 1996-09-26 Basf Ag Verfahren zur Herstellung von Wirkstoffzubereitungen in Form einer festen Lösung des Wirkstoffs in einer Polymermatrix sowie mit diesem Verfahren hergestellte Wirkstoffzubereitungen
US5874029A (en) * 1996-10-09 1999-02-23 The University Of Kansas Methods for particle micronization and nanonization by recrystallization from organic solutions sprayed into a compressed antisolvent
IL124935A (en) * 1996-05-20 2001-06-14 Janssen Pharmaceutica Nv Dispersible antifungal compositions comprising itraconazole with improved bioavailability
US6787157B1 (en) * 1998-03-10 2004-09-07 Abbott Laboratories Multiphase active ingredient-containing formulations
US8551526B2 (en) * 2000-11-03 2013-10-08 Board Of Regents, The University Of Texas System Preparation of drug particles using evaporation precipitation into aqueous solutions
US20030054042A1 (en) * 2001-09-14 2003-03-20 Elaine Liversidge Stabilization of chemical compounds using nanoparticulate formulations
DE10208344A1 (de) * 2002-02-27 2003-09-04 Roehm Gmbh Schmelzextrusion von Wirkstoffsalzen
GB0310300D0 (en) * 2003-05-06 2003-06-11 Univ Belfast Nanocomposite drug delivery composition
GB0519350D0 (en) * 2005-09-22 2005-11-02 Boots Healthcare Int Ltd Therapeutic agents
NZ566419A (en) * 2005-09-23 2010-03-26 Hoffmann La Roche Novel dosage formulation
US9198865B2 (en) * 2006-01-19 2015-12-01 Dow Global Technologies Llc Biologically active composition comprising ethylcellulose

Also Published As

Publication number Publication date
KR20100134557A (ko) 2010-12-23
WO2009087410A3 (en) 2009-09-17
AU2009203627A1 (en) 2009-07-16
PE20091550A1 (es) 2009-10-03
EP2249808A2 (en) 2010-11-17
CN101951891A (zh) 2011-01-19
JP2011509283A (ja) 2011-03-24
AP2010005341A0 (en) 2010-08-31
ZA201005015B (en) 2011-03-30
WO2009087410A2 (en) 2009-07-16
CO6290635A2 (es) 2011-06-20
PA8812601A1 (es) 2009-08-26
MX2010007645A (es) 2010-11-05
CA2712010A1 (en) 2009-07-12
US20110028456A1 (en) 2011-02-03

Similar Documents

Publication Publication Date Title
BRPI0905717A2 (pt) Composição farmacêutica, processo para preparar uma composição farmacêutica e forma de dosagem farmacêutica
BRPI1007161A2 (pt) composição farmacêutica oral, e processo para preparar uma composição
BRPI0914918A2 (pt) forma de dosagem farmacêutica, e, método para preparar uma forma de dosagem sólida.
BRPI1011764A2 (pt) composição farmacêutica, e, método para preparar uma composição farmacêutica
BRPI1007211A2 (pt) composição farmacêutica oral em uma forma sólida, e, processo para preparar uma composição.
BRPI0818533A2 (pt) composto, composição farmacêutica, e, processo para a preparação de um composto
BRPI0909691A2 (pt) Composto, método para preparar um composto, e, composição farmacêutica
BRPI0912384A2 (pt) composição, e, método para preparar uma composição
BRPI0924136A2 (pt) composição farmacêutica sólida compreendendo amlodipina e losartan e processo para a produção da mesma
BRPI0812064A2 (pt) Formulação farmacêutica, tabletes, e, processo para a produção de uma formulação farmacêutica
BRPI0919466A2 (pt) composição farmacêutica para liberação modificada
BRPI0908092A2 (pt) Edulcorante, método para preparar uma composição edulcorante, e, composição edulcorante
BRPI0918971A2 (pt) tienopirimidinas para composições farmacêuticas
BRPI1016132A2 (pt) composição, formulação farmacêutica, método para fabricar uma formulação farmacêutica estável.
BRPI0905847A2 (pt) "composição farmacêutica injetável e processo para preparar a composição"
BR112012002102A2 (pt) composição farmaceutica e metodo para preparar uma composição farmaceutica
BRPI0910545A2 (pt) processo contínuo para fazer composições farmacêuticas
BRPI0814163A2 (pt) Processo para a preparação de compostos, forma cristalina, e, composição farmacêutica
BRPI0818680A2 (pt) composição farmacêutica, preparação farmacêutica, e método para preparar um forma de dosagem oral farmacêutica
BR112013008008A2 (pt) composto, composição farmacêutica e processo para preparar um composto
BRPI0814821A2 (pt) Composto, composição farmacêutica, e, processo para preparar um composto
BRPI0925100A2 (pt) forma de dosagem osmótica e processo para preparar uma forma de dosagem osmótica
BRPI1010707A2 (pt) composição farmacêutica, processo para o preparo da mesma, processo para o preparo de uma formulação injetável e formulação injetável
CO6801754A2 (es) Una composición farmacéutica para tratar una enfermedad en la cavidad oral que comprende rebamipida
BRPI0923574A2 (pt) processo para a preparação de uma forma em pó de peptídeo

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 4A, 5A, 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2344 DE 08-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.